Triphase Accelerator Corporation Announces Preclinical Data On Proteasome Inhibitor Marizomib At 2014 American Society of Clinical Oncology Annual Meeting
5/30/2014 7:36:32 AM
Triphase Accelerator Corporation, a private drug development accelerator dedicated to advancing compelling, well-differentiated drugs through Phase II proof-of-concept, today announced preclinical study results demonstrating that the combination of marizomib, Triphase’s highly-differentiated proteasome inhibitor, and pomalidomide (Pomalyst®) was synergistic in killing multiple myeloma cells. The marizomib data will be presented on Monday, June 2, in a poster session at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting in Chicago.
Help employers find you! Check out all the jobs and post your resume.
comments powered by